Dietary natural products as emerging lipoprotein(a)-lowering agents

Amir Abbas Momtazi-Borojeni, Niki Katsiki, Matteo Pirro, Maciej Banach, Khalid Al Rasadi, Amirhossein Sahebkar

Research output: Contribution to journalArticlepeer-review

23 Citations (Scopus)


Elevated plasma lipoprotein(a) (Lp(a)) levels are associated with an increased risk of cardiovascular disease (CVD). Hitherto, niacin has been the drug of choice to reduce elevated Lp(a) levels in hyperlipidemic patients but its efficacy in reducing CVD outcomes has been seriously questioned by recent clinical trials. Additional drugs may reduce to some extent plasma Lp(a) levels but the lack of a specific therapeutic indication for Lp(a)-lowering limits profoundly reduce their use. An attractive therapeutic option is natural products. In several preclinical and clinical studies as well as meta-analyses, natural products, including l-carnitine, coenzyme Q 10 , and xuezhikang were shown to significantly decrease Lp(a) levels in patients with Lp(a) hyperlipoproteinemia. Other natural products, such as pectin, Ginkgo biloba, flaxseed, red wine, resveratrol and curcuminoids can also reduce elevated Lp(a) concentrations but to a lesser degree. In conclusion, aforementioned natural products may represent promising therapeutic agents for Lp(a) lowering.
Original languageEnglish
Pages (from-to)12581-12594
Number of pages14
JournalJournal of Cellular Physiology
Issue number8
Publication statusPublished - Aug 1 2019


  • cardiovascular disease
  • coenzyme Q10
  • l-carnitine
  • lipoprotein(a)
  • natural products
  • nutraceuticals
  • resveratrol


Dive into the research topics of 'Dietary natural products as emerging lipoprotein(a)-lowering agents'. Together they form a unique fingerprint.

Cite this